Story perspectives

FDA Halts Vaccine Study Releases; Pfizer Anaphylaxis, Moderna Seizure Risks

5/7/2026

Summary

Story summary

The FDA halted release of vaccine studies after HHS spokesperson Andrew Nixon said the authors’ conclusions exceeded data and covered COVID-19 and shingles vaccines.
A Medicare analysis of 7.5 million found a rare anaphylaxis increase—about 1 per million—after the 2023-2024 Pfizer-BioNTech COVID-19 vaccine and no other significant risks.
An abstract reported a rise in febrile seizures among children 6 months to 5 years after Moderna vaccination, prompting its October withdrawal from Vaccine.

1 of 1

Story summary

The FDA halted release of vaccine studies after HHS spokesperson Andrew Nixon said the authors’ conclusions exceeded data and covered COVID-19 and shingles vaccines.
A Medicare analysis of 7.5 million found a rare anaphylaxis increase—about 1 per million—after the 2023-2024 Pfizer-BioNTech COVID-19 vaccine and no other significant risks.
An abstract reported a rise in febrile seizures among children 6 months to 5 years after Moderna vaccination, prompting its October withdrawal from Vaccine.